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with respect to wild-type animals fed water, and the enrichment with
fructose exclusively caused the restoration of the significantly increased
levels of these two parameters. These results clearly suggest that the
presence of TLR-4 is essential to explain liver damage, body weight
gain, and ALT impairment due to the fructose intake.
Furthermore, the authors found that plasma endotoxin levels were
significantly increased both in wild-type and mutant mice fed chron-
ically with a 30% fructose solution, in comparison to water-fed con-
trols.
The role of fructose in NAFLD development was not entirely un-
known to researchers. In particular, a recent work4 demonstrates that
patients with NAFLD have a significantly greater consumption of
fructose than controls, and an increased hepatic expression of fructoki-
nase messenger RNA. Although the role of TLR-4 in carbohydrate-
dependent NAFLD has been only recently suggested by Thuy and
colleagues,5 they have pinpointed one of the potential mechanisms
through which fructose could participate in NAFLD development and
progression in humans: a carbohydrate-rich diet may produce ethanol
when intestinal stasis favors bacterial overgrowth in the upper parts of
the gastrointestinal tract. The increased portal endotoxemia could ini-
tiate TLR signaling and induce necroinflammation, which character-
izes steatohepatitis, the most advanced form of NAFLD. Accordingly,
this study also highlighted significant correlations between hepatic
expression of TLR-4, plasminogen activator inhibitor 1, and endo-
toxin, even though they are still unable to explain the molecular sig-
naling pathways.
Interestingly, another recent study investigated the potential im-
portance of Kupffer cells and TLR-4 in the pathogenic mechanisms
underlying nonalcoholic steatohepatitis induced by a methionine-de-
ficient and choline-deficient diet.6
Unfortunately, the study by Spruss et al. does not provide ad-
ditional clues to the mechanisms by which fructose intake, endox-
emia, and the resulting activation of TLR-4 signaling might
promote NAFLD. On the other hand, the experimental results in
this work allow the exclusion of the involvement of some important
TLR-4 – dependent proinflammatory inducing transcriptional fac-
tors (i.e., IRF3 and IF37), suggesting that fructose feeding may lead
to NAFLD through an insulin-independent de novo lipogenesis
and/or an endotoxin-dependent activation of Kupffer cells. In this
last hypothesis, an interaction network which involves TLR-4,
Myd88, c-Jun N-terminal kinase, and nuclear factor B might
induce tumor necrosis factor-alpha production and release, oxida-
tive stress, and insulin resistance.7
We believe that although Spruss et al. present a well-conducted
study, the precise role of TLR-4–dependent pathways in NAFLD
requires further experimentation. In fact, it is possible that new addi-
tional signaling proteins of innate immunity, as yet uncovered, may be
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Noninvasive Assessment of Liver Disease Severity With Liver Fat Score and CK-18 In NAFLD:
Prognostic Value of Liver Fat Equation Goes Beyond Hepatic Fat Estimation
To the Editor:
We read with interest the article by Kotronen et al.,1 reporting on
liver fat score and liver fat equation—new noninvasive, easy-to-calcu-
late indexes that estimate the presence and severity of hepatic fat accu-
mulation. We assessed the ability of these two indexes and of plasma
cytokeratin-18 fragments (CK-18) to predict the presence of nonalco-
holic fatty liver disease (NAFLD) and of nonalcoholic steatohepatitis
(NASH),1,2 respectively, and their relations to validated predictors of
incident cardiovascular disease and diabetes.3,4
To this purpose, 125 subjects (40 nondiabetic patients with biopsy-
proven NAFLD and 85 healthy controls) underwent an oral fat toler-
ance test,5 with measurement of postprandial plasma lipid responses,
and a standard oral glucose tolerance test (OGTT), whose results were
elaborated by Minimal Model analysis to assess whole-body, hepatic,
and muscle insulin sensitivity and indexes of pancreatic -cell function
(namely, CP-genic index [CGI] and Adaptation Index [AI]), as previ-
ously described.5-7 Finally, circulating markers of inflammation (C-
reactive protein), endothelial dysfunction (E-selectin and intercellular
adhesion molecule-1 [ICAM-1]) and oxidative stress (nitrotyrosine
and oxidized low-density lipoproteins) were measured.
Results are shown in Table 1. NASH group showed higher post-
prandial lipemia and oxidative stress than either steatosis or controls.
Patients with NASH had also more severe whole-body insulin resis-
tance, hepatic insulin resistance, and pancreatic -cell dysfunction and
higher plasma C-reactive protein, E-selectin, ICAM-1, and nitroty-
rosine levels than steatosis and control groups.
Liver fat equation correlated with the degree of histological steato-
sis in both NASH and steatosis groups (in both groups: rs  0.66, P 
0.003). The area under the receiver operating characteristic curve (AU-
ROC) of liver fat score for predicting NAFLD was 0.86 (95% confi-
dence interval [CI]: 0.82-0.91). A cutoff of 0.640 individuated
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NAFLD with a sensitivity, specificity, and positive and negative like-
lihood ratio of 0.93, 0.80, 4.63, and 0.09, respectively.
The AUROC of CK-18 for NASH was 0.83 (95% CI: 0.80-0.90).
A cutoff of 246 IU/L for CK-18 individuated NASH with a sensitivity,
specificity, and positive and negative likelihood ratio of 0.78, 0.88,
6.65, and 0.25, respectively.
On multiple regression analysis, liver fat equation independently
correlated with hepatic insulin resistance (  0.52; 95% CI: 0.48-
0.56, P  0.005) and with indexes of pancreatic -cell function (for
CGI:   0.43; 95% CI: 0.48-0.56, P  0.01; for AI:   0.46;
95% CI: 0.42-0.51, P  0.009) in the whole sample. Liver fat equa-
tion also independently predicted plasma C-reactive protein ( 
0.40; 95% CI: 0.37-0.44, P  0.02), nitrotyrosine (  0.41; 95%
CI: 0.38-0.46, P  0.02), E-selectin (  0.49; 95% CI: 0.45-0.54,
P  0.006), and postprandial triglyceride (  0.42; 95% CI: 0.39-
0.46, P  0.02) and oxidized low-density lipoprotein (  0.40; 95%
CI: 0.38-0.45, P  0.03) responses to the fat load.
Histological steatosis, inflammatory grade, and fibrosis stage were
not independently related to the abovementioned parameters.
In conclusion, liver fat equation and CK-18 accurately individu-
ated the presence and severity of liver fat infiltration and the presence
of NASH in our cohort of nondiabetic subjects. Most importantly,
liver fat equation was tightly related to validated predictors of increased
cardiometabolic risk in both healthy and NAFLD subjects. The clini-
Table 1. Baseline Characteristics of Patients with NAFLD and Controls
Characteristic Controls (n  85) Steatosis (n  17) NASH (n  23) P Value
Age (years) 49  4 48  3 46  4 0.712
Sex (%males) 67 70 71 0.549
BMI (kg/m2) 25.1  1.7 24.9  1.6 25.3  1.5 0.656
Systolic BP (mmHg) 129  6 130  7 131  9 0.978
Diastolic BP (mmHg) 81  4 84  6 88  6* 0.034
Waist (cm) 88  2 90  4 91  4 0.478
Tg (mg/dL) 89  21 98  35 111  39* 0.112
LDL-C (mg/dL) 99  7 124  8 150  7* 0.056
HDL-C (mg/dL) 59  2 57  2 49  2* 0.013
Total C (mg/dL) 156  9 205  9 241  10† 0.058
Glucose (mg/dL) 92  3 96  3 97  4 0.541
Insulin (U/mL) 4.2  1.6 14.3  2.9† 22.7  5.6† 0.009
AST (U/L) 13  3 56  3† 42  3† 0.123
ALT (U/L) 16  5 127  8† 116  8† 0.245
ICAM-1 (mg/mL) 190.5  7.1 220.4  7.2* 264.4  8.7† 0.031
E-selectin (mg/mL) 18.9  2.0 23.1  2.3† 38.2  2.5† 0.001
C-reactive protein 1.1  0.7 1.6  1.0* 2.4  1.1† 0.028
CK-18 (IU/L) (IU/L)fragments 98  6 136  11 253  12† 0.030
Nitrotyrosine 3.1  3.7 9.9  4.1* 27.4  7.3† 0.002
Met sy (%) 21 36 47† 0.052
Histological steatosis (% hepatocytes) – 167 339 0.032
Necroinflammatory grade – – 2.10.3 –
Fibrosis stage – – 1.90.4 –
Liver fat score 2.428  0.112 1.563  0.290† 5.114  0.931† 0.039
Liver fat (%) 1.5  1 13  3† 30  6† 0.025
OGTT-derived indexes of glucose homeostasis
OGIS (mL  minute–1  m–2) 459.1  16.5 400  11.9* 369  10.2† 0.032
Hepatic extraction (%) 78  4 81  5 70  4* 0.030
Cpgenic Index (CGI) (ngC-pep  g–1glucose) 614  36.1 540  29.5 402  19.3† 0.009
Adaptation Index (ngC-pep  g–1glucose 
mL
–1
 m–2) (ngCpep  g–1glucose 
mL
–1
 m–2) 281826  15391 216703  12678 148401  10681† 0.007
Muscle insulin sensitivity 0.032  0.009 0.016  0.008* 0.015  0.006* 0.267
Hepatic insulin resistance 738  96 1109  112† 1812  183† 0.011
Oral Fat Load
IAUC Tg (mg/dL  hour) 124  28 344  49 398  56 0.034
Fasting FFA (mol/L) 0.47  0.13 1.09  0.22 1.96  0.29 0.112
IAUC FFA (mol/L  hour) 0.8  0.3 2.5  0.5 4.9  0.9 0.009
Fasting oxidizedLDL (uA 234 nm/uA
200 nm  100) 6.42  1.63 6.44  1.23 7.94  2.59 0.356
IAUC oxidized LDL (uA 234 nm/uA 200
nm  100  hour) 1.29  0.51 4.29  1.25 8.02  1.93 0.001
Data are presented as mean  standard error of the mean. Differences between groups were analyzed by analysis of variance for normal variables; otherwise, the
Mann-Whitney test was used for nonparametric variables. Normality was evaluated by Shapiro-Wilk test. Fisher or chi-squared test were used to compare categorical
variables, as appropriate. Differences were considered statistically significant at P  0.05.
BP, blood pressure; FFA, free fatty acids; HDL-C, high-density lipoprotein cholesterol; IAUC, incremental area under the curve; ICAM-1, intercellular adhesion
molecule-1; LDL-C, low-density lipoprotein cholesterol; met sy, metabolic syndrome; OGIS, oral glucse insulin sensitivity index; Tg, triglyceride; total C, total cholesterol.
CGI (Cpgenic index)  C – peptide30/glucose30 during the OGTT; Adaptation Index was computed by multiplying CGI  OGIS. Hepatic extraction is the percent
secreted insulin extracted by the liver.
*P  0.05 versus controls; †P  0.01 versus controls.
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cal significance of liver fat equation may thus go beyond hepatic fat
content estimation and this easy-to-calculate index may aid in predict-
ing individual cardio-metabolic risk of patients with NAFLD. Our
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Serum Markers of Hepatocyte Apoptosis: Current Terminology and Predictability in Clinical Practice
To the Editor:
We read with interest the article by Feldstein et al.,1 in which they
validated the use of cytokeratin-18 (CK-18) fragment serum levels as a
noninvasive biomarker for the diagnosis of nonalcoholic steatohepati-
tis (NASH) in a large cohort of adults with biopsy-proven nonalco-
holic fatty liver disease (NAFLD). According to their conclusions, this
test can be reliably used to diagnose NASH among patients with sus-
pected NAFLD in clinical practice. This is an important study, because
it confirms the significant associations between high CK-18 fragment
levels and NASH reported in previous smaller studies in other cohorts
of adults2,3 or even children with NAFLD.4 However, we would like to
draw your attention to two issues: terminology and predictability.
The “Keratin Nomenclature Committee” recently established the
new consensus nomenclature for mammalian keratin genes and pro-
teins,5 which is based on and extends the first comprehensive keratin
nomenclature developed back in 1982.6 According to this new nomen-
clature, which is in agreement with the nomenclature of the Human
Genome Organisation (HUGO) for both gene and protein names,5 it
is suggested the term “keratin” be used instead of “cytokeratin”, be-
cause it covers all intermediate filament-forming proteins with specific
physicochemical properties produced in any vertebrate epithelia.5
Thus, the term “keratin-18 (K-18)” is now more appropriate than
“cytokeratin-18 (CK-18)” for all manuscripts.
K-18 and keratin-8 (K-8) are the only cytoplasmic intermediate
filaments of hepatocytes but are not hepatocyte-specific, because they
are also expressed in most simple epithelial cells including bile duct
cells.7 K-18 fragment serum levels, which are increasingly used as a
biomarker of hepatocyte apoptosis, are also not liver-specific, because
these levels may be elevated in patients with epithelial tumors.8 More-
over, this marker is not specific for NASH, because it is increased in
several liver diseases with ongoing necroinflammation and fibrosis,
such as chronic hepatitis C or B.9,10
The specificity issues are substantially limited if the test is used in
patients with probable NAFLD. However, even in such patients fol-
lowed in specialized centers, its diagnostic accuracy does not seem to be
excellent. In the study by Feldstein et al.,1 the area under the receiver
operating characteristic (AUROC) curve for NASH diagnosis was
0.83 (not excellent) with sensitivity and specificity values of 75% and
81% or 65% and 92% for cutoff values of 246 or 292 U/L, respec-
tively. In 58 adult patients with NAFLD studied in our center, K-18
fragment levels offered an AUROC curve of 0.87 and sensitivity and
specificity values of 60% and 93%, respectively, for a cutoff of 250 U/L
(G. V. Papatheodoridis, unpublished data). Similar findings for vari-
able cutoff values were previously reported by others with the best
results reported in the first relevant study.2,3 Thus, measurement of
K-18 fragment levels will probably be helpful in the noninvasive diag-
nosis of NAFLD, particularly in cases with rather high levels. The
specificity issues should be restricted by ensuring the NAFLD diagno-
sis, but a decision may not be easy in a large proportion of NAFLD
cases with K-18 values of 300 U/L, and particularly 200 U/L.
DINA G. TINIAKOS1
GEORGE V. PAPATHEODORIDIS2
1Laboratory of Histology and Embryology
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